Page 75 - Read Online

Page 22 of 25 Torres et al. J Cancer Metastasis Treat 2018;4:4 I http://dx.doi.org/10.20517/2394-4722.2017.49

161. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and
progression in individual patients with stage Ta T1 bladder cancer using eortc risk tables: a combined analysis of 2596 patients from
seven EORTC trials. Eur Urol 2006;49:466-77.
162. Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, Prescott S, Kirkali Z, van de Beek C, Gorlia T, de Reijke
TM; EORTC Genito-Urinary Tract Cancer Group. Long-term efficacy results of eortc genito-urinary group randomized phase 3 study
30911 comparing intravesical instillations of epirubicin, bacillus calmette-guérin, and bacillus calmette-guérin plus isoniazid in patients
with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57:766-73.
163. Babjuk M, Burger M, Zigeuner R, Shariat S, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, Rouprêt M;
European Association of Urology. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol
2013;64:639-53.
164. Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, Gontero P, Turkeri L, Marreaud S, Collette S, Oosterlinck
W. Side Effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the
bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1
year with 3 years of maintenance BCG. Eur Urol 2014;65:69-76.
165. Redelman-Sidi G, Glickman M, Bochner B. The mechanism of action of BCG therapy for bladder cancer-a current perspective. Nat Rev
Urol 2014;11:153-62.
166. Kawai K, Miyazaki J, Joraku A, Nishiyama H, Akaza H. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current
understanding and perspectives on engineered BCG vaccine. Cancer Sci 2013;104:22-7.
167. Pandith AA, Khan NP, Azad NA, Khan MS, Wani MS. Association of chemokine and chemokine receptor gene polymorphis (MCP1
A-2518G and CCR2-V64I) with urinary bladder cancer: a study in kashmiri population. Am J Mol Cell Biol 2013;2:1-13.
168. Fuge O, Vasdev N, Allchorne P, Green JS. Immunotherapy for bladder cancer. Res Rep Urol 2015;7:65-79.
169. Bunimovich-Mendrazitsky S, Halachmi S, Kronik N. Improving Bacillus Calmette-Guérin (BCG) immunotherapy for bladder cancer
by adding interleukin 2 (IL-2): a mathematical model. Math Med Biol 2016;33:159-88.
170. Iqbal NT, Hussain R. Non-specific immunity of BCG vaccine: a perspective of BCG immunotherapy. Trials Vaccinol 2014;3:143-9.
171. Kates M, Nirschl T, Sopko NA, Matsui H, Kochel CM, Reis LO, Netto GJ, Hoque MO, Hahn NM, McConkey DJ, Baras AS, Drake CG,
Bivalacqua TJ. Intravesical BCG Induces CD4 + T-cell expansion in an immune competent model of bladder cancer. Cancer Immunol
Res 2017;5:594-603.
172. Gandhi NM, Morales A, Lamm DL. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer. BJU Int 2013;112:288-97.
173. Amarante-Mendes GP, Griffith TS. Therapeutic applications of TRAIL receptor agonists in cancer and beyond. Pharmacol Ther
2015;155:117-31.
174. Liu X, Dowell AC, Patel P, Viney RP, Foster MC, Porfiri E, James ND, Bryan RT. Cytokines as effectors and predictors of responses in
the treatment of bladder cancer by bacillus Calmette-Guérin. Future Oncol 2014;10:1443-56.
175. Nemunaitis J, Cunningham C, Senzer N, Kuhn J, Cramm J, Litz C, Cavagnolo R, Cahill A, Clairmont C, Sznol M. Pilot trial of
genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene
Ther 2003;10:737-44.
176. Schmitz-Winnenthal FH, Hohmann N, Niethammer A, Friedrich T, Lubenau H, Springer M, Breiner KM, Mikus G, Weitz J, Ulrich A,
Buechler MW, Pianka F, Klaiber U, Diener M, Leowardi C, Schimmack S, Sisic L, Keller AV, Koc R, Springfeld C, Knebel P, Schmidt
T, Ge Y, Bucur M, Stamova S, Podola L, Haefeli WE, Grenacher L, Beckhove P. Anti-angiogenic activity of VXM01, an oral T-cell
vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial. Onco
Immunol 2015;4:e1001217.
177. Le DT, Brockstedt D, Nir-Paz RG, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL,
Sugar EA, Pons A, Cox AL, Levine J, Murphy AL, Illei P, Dubensky TW Jr, Eiden JE, Jaffee EM, Laheru DA. A live-attenuated listeria
vaccine (ANZ-100) and a live-attenuated listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of
safety and immune induction. Clin Cancer Res 2011;18:858-68.
178. Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN,
Laheru DA, Lutz ER, Solt S, Murphy AL, Skoble J, Lemmens E, Grous J, Dubensky T Jr, Brockstedt DG, Jaffee EM. Safety and
survival with GVAX pancreas prime and listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic
pancreatic cancer. J Clin Oncol 2015;33:1325-33.
179. Pollheimer M, Kornprat P, Lindtner R, Harbaum L, Schlemmer A, Rehak P, Langner C. Tumor necrosis is a new promising prognostic
factor in colorectal cancer. Hum Pathol 2010;41:1749-57.
180. Ladstein RG, Bachmann IM, Straume O, Akslen LA. Tumor necrosis is a prognostic factor in thick cutaneous melanoma. Am J Surg
Pathol 2012;36:1477-82.
181. Swinson D, Jones J, Richardson D, Cox G, Edwards J, O’Byrne K. Tumour necrosis is an independent prognostic marker in non-small
cell lung cancer: correlation with biological variables. Lung Cancer 2002;37:235-40.
182. Staedtke V, Bai RY, Sun W, Huang J, Kibler KK, Tyler BM, Gallia GL, Kinzler K, Vogelstein B, Zhou S, Riggins GJ. Clostridium
novyi-NT can cause regression of orthotopically implanted glioblastomas in rats. Oncotarget 2015;6:5536-46.
183. Krick EL, Sorenmo KU, Rankin SC, Cheong I, Kobrin B, Thornton K, Kinzler KW, Vogelstein B, Zhou S, Diaz LA Jr. Evaluation of
Clostridium novyi -NT spores in dogs with naturally occurring tumors. Am J Vet Res 2012;73:112-8.
184. Kubiak A, Minton N. The potential of clostridial spores as therapeutic delivery vehicles in tumour therapy. Res Microbiol 2015;166:244-54.